Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2019

Open Access 01-12-2019 | Prostate Cancer | Primary research

Combined analysis and validation for DNA methylation and gene expression profiles associated with prostate cancer

Authors: Yanqiu Tong, Yang Song, Shixiong Deng

Published in: Cancer Cell International | Issue 1/2019

Login to get access

Abstract

Background

Prostate cancer (PCa) is a malignancy cause of cancer deaths and frequently diagnosed in male. This study aimed to identify tumor suppressor genes, hub genes and their pathways by combined bioinformatics analysis.

Methods

A combined analysis method was used for two types of microarray datasets (DNA methylation and gene expression profiles) from the Gene Expression Omnibus (GEO). Differentially methylated genes (DMGs) were identified by the R package minfi and differentially expressed genes (DEGs) were screened out via the R package limma. A total of 4451 DMGs and 1509 DEGs, identified with nine overlaps between DMGs, DEGs and tumor suppressor genes, were screened for candidate tumor suppressor genes. All these nine candidate tumor suppressor genes were validated by TCGA (The Cancer Genome Atlas) database and Oncomine database. And then, the gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes pathway (KEGG) enrichment analyses were performed by DAVID (Database for Annotation, Visualization and Integrated Discovery) database. Protein–protein interaction (PPI) network was constructed by STRING and visualized in Cytoscape. At last, Kaplan–Meier analysis was performed to validate these genes.

Results

The candidate tumor suppressor genes were IKZF1, PPM1A, FBP1, SMCHD1, ALPL, CASP5, PYHIN1, DAPK1 and CASP8. By validation in TCGA database, PPM1A, DAPK1, FBP1, PYHIN1, ALPL and SMCHD1 were significant. The hub genes were FGFR1, FGF13 and CCND1. These hub genes were identified from the PPI network, and sub-networks revealed by these genes were involved in significant pathways.

Conclusion

In summary, the study indicated that the combined analysis for identifying target genes with PCa by bioinformatics tools promote our understanding of the molecular mechanisms and underlying the development of PCa. And the hub genes might serve as molecular targets and diagnostic biomarkers for precise diagnosis and treatment of PCa.
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
5.
Lo KW, Huang DP. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol. 2002;12(6):451–62.PubMedCrossRef
6.
7.
Wang Qian, Wang Gang, Liu Chaoxu, He Xianli. Prognostic value of CpG island methylator phenotype among hepatocellular carcinoma patients: a systematic review and meta-analysis. Int J Surg. 2018;54:92–9.PubMedCrossRef
8.
Yang X, Han H, De Carvalho D, et al. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell. 2014;26(4):585.CrossRef
9.
Maunakea AK, Nagarajan RP, Bilenky M, et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature. 2010;466(7303):253–7.PubMedPubMedCentralCrossRef
10.
Aran V, Victorino AP, Thuler LC, Ferreira CG. Colorectal cancer: epidemiology, disease mechanisms and interventions to reduce onset and mortality. Clin Colorectal Cancer. 2016;15(3):195–203.PubMedCrossRef
11.
Decarvalho D, Sharma S, You JS, et al. DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell. 2012;21(5):655.CrossRef
12.
13.
Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol. 2008;5:588–99.PubMedCrossRef
14.
Nannini M, Pantaleo MA, Maleddu A, et al. Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev. 2009;35:201–9.PubMedCrossRef
15.
Bustin SA, Dorudi S. Gene expression profiling for molecular staging and prognosis prediction in colorectal cancer. Exp Rev Mol Diagn. 2004;4:599–607.CrossRef
16.
Carmona FJ, Azuara D, Berenguer-Llergo A, Fernandez AF, Biondo S, de Oca J, Rodriguez-Moranta F, Salazar R, Villanueva A, Fraga MF, et al. DNA methylation biomarkers for noninvasive diagnosis of colorectal cancer. Cancer Prev Res. 2013;6(7):656–65.CrossRef
17.
Lascorz J, Hemminki K, Forsti A. Systematic enrichment analysis of gene expression profiling studies identifies consensus pathways implicated in colorectal cancer development. J Carcinog. 2011;10:7.PubMedPubMedCentralCrossRef
18.
Iwaya T, Yokobori T, Nishida N, et al. Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway. Carcinogenesis. 2012;33(12):2391–7.PubMedCrossRef
19.
Irizarry RA. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249–64.PubMedCrossRef
20.
Benjamini Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. 1995;57:289–300.
21.
Glynn Dennis J, Sherman BT, Hosack DA, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4(5):3.CrossRef
22.
Gene Ontology C. The gene ontology (GO) project in 2006. Nucleic Acids Res. 2006;34:322–6.CrossRef
23.
24.
25.
26.
Wilder SP, Kaisaki PJ, Argoud K, et al. Comparative analysis of methods for gene transcription profiling data derived from different microarray technologies in rat and mouse models of diabetes. BMC Genomics. 2009;10(1):63.PubMedPubMedCentralCrossRef
27.
Michael KL, Taylor LC, Schultz SL, Walt DR. Randomly ordered addressable high-density optical sensor arrays. Anal Chem. 1998;70(7):1242–8.PubMedCrossRef
28.
Leek JT, Scharpf RB, Bravo HC, et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet. 2010;11(10):733–9.PubMedCrossRef
29.
Bardou P, Mariette J, Escudié F, et al. jvenn: an interactive Venn diagram viewer. BMC Bioinform. 2014;15(1):1–7.CrossRef
30.
Min Z, Kim P, Mitra R, et al. TSGene 2.0: an updated literature-based knowledgebase for tumor suppressor genes. Nucleic Acids Res. 2016;44(Database issue):D1023–31.
31.
Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18(11):1427–31.PubMedCrossRef
32.
Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Rodriguez IP, Chakravarthi BVSK, Varambally S. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–58.PubMedPubMedCentralCrossRef
33.
Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2015;69:428–35.PubMedPubMedCentralCrossRef
34.
Flocks RH, Urich VC, Patel CA, et al. Studies on the antigenic properties of prostatic tissue. J Urol. 1960;84(1):134.PubMedCrossRef
35.
Pérez-Ibave DC, Burciaga-Flores CH, Elizondo-Riojas MÁ. Prostate-specific antigen (PSA) as a possible biomarker in non-prostatic cancer: a review. Cancer Epidemiol. 2018;54:48–55.PubMedCrossRef
36.
Flocks RH, et al. Studies on spermagglutinating antibodies in antihuman prostate sera. J Urol. 1962;87:475–8.PubMedCrossRef
37.
Catalona WJ. History of the discovery and clinical translation of prostate-specific antigen. Asian J Urol. 2014;1(1):12–4.PubMedCrossRef
38.
Tokudome S, Ando R, Koda Y. Discoveries and application of prostate-specific antigen, and some proposals to optimize prostate cancer screening. Cancer Manag Res. 2018;8:45–7.
39.
Ablin RJ, et al. Precipitating antigens of the normal human prostate. J Reprod Fertil. 1970;22(3):573–4.PubMedCrossRef
40.
Li TS, Beling CG. Isolation and characterization of two specific antigens of human seminal plasma. Fertil Steril. 1973;24(2):134–44.PubMedCrossRef
41.
Sokoll L J, Chan D W. Prostate-specific antigen. Its discovery and biochemical characteristics. Urologic Clinics of North America. 1997; 24(2):253-259.
42.
Sensabaugh GF. Isolation and characterization of a semen-specific protein from human seminal plasma: a potential new marker for semen identification. J Forensic Sci. 1978;23(1):106–15.PubMedCrossRef
43.
Sensabaugh GF, Blanke ET. Seminal plasma protein p30: simplified purification and evidence for identity with prostate specific antigen. J Urol. 1990;144(6):1523–6.PubMedCrossRef
44.
Fu G, Tang J, Wang M, et al. CASP8 promoter polymorphism, mRNA expression and risk of prostate cancer among Chinese men. J Biomed Res. 2011;25(2):128–34.PubMedPubMedCentralCrossRef
45.
46.
Noel EE, Yeste-Velasco M, Mao X, et al. The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am J Pathol. 2010;176(6):69.CrossRef
47.
Borst P, Rottenberg S, Jonkers J. How do real tumors become resistant to cisplatin? Cell Cycle. 2008;7:1353–9.PubMedCrossRef
48.
Houldsworth J, Korkola JE, Bosl GJ, et al. Biology and genetics of adult male germ cell tumors. J Clin Oncol. 2006;24(35):5512–8.PubMedCrossRef
49.
Tan C, Hu W, He Y, et al. Cytokine-mediated therapeutic resistance in breast cancer. Cytokine. 2018;108:151–9.PubMedCrossRef
50.
Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today. 1999;20(10):469–73.PubMedCrossRef
51.
Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457(7231):910–4.PubMedPubMedCentralCrossRef
52.
Sherman MH, Yu RT, Engle DD, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 2014;159(1):80.PubMedPubMedCentralCrossRef
53.
Bristol ML, Di X, Beckman MJ, et al. Dual functions of autophagy in the response of breast tumor cells to radiation: cytoprotective autophagy with radiation alone and cytotoxic autophagy in radiosensitization by vitamin D3. Autophagy. 2012;8(5):739.PubMedPubMedCentralCrossRef
54.
Cai-Ning Z, Ya L, Xiao M, et al. Insight into the roles of vitamins C and D against cancer: myth or truth? Cancer Lett. 2018;431:161–70.CrossRef
55.
56.
Whitburn J, Rao S, Tabata S, et al. The prostate cancer-bone environment causes upregulation of the pentose phosphate pathway. Eur Urol Suppl. 2017;16(3):e152–3.CrossRef
57.
Abidi SH, Bilwani F, Ghias K, et al. Viral etiology of prostate cancer: genetic alterations and immune response. A literature review. Int J Surg. 2018;52:136.PubMedCrossRef
58.
Claire VB, Sandra D, Formenti SC, et al. Cytosolic dna sensing in organismal tumor control. Cancer Cell. 2018;34(3):361–78.CrossRef
59.
Ying KC, Gack MU. Viral evasion of intracellular DNA and RNA sensing. Nat Rev Microbiol. 2016;14(6):360–73.CrossRef
60.
61.
Li Q, Ingram L, Kim S, et al. Paracrine fibroblast growth factor initiates oncogenic synergy with epithelial FGFR/Src transformation in prostate tumor progression 12. Neoplasia. 2018;20(3):233–43.PubMedPubMedCentralCrossRef
62.
63.
Bova GS, Kallio HML, Annala M, et al. Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer. Cold Spring Harb Mol Case Stud. 2016;2(3):a000752.PubMedPubMedCentralCrossRef
64.
François B, Catherine N, Gwenaëlle G, et al. FGFR1 and WT1 are markers of human prostate cancer progression. BMC Cancer. 2006;6(1):272.CrossRef
65.
Hu M, Polyak K. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004;6(1):17–32.PubMedCrossRef
66.
Hoek K, Rimm DL, Williams KR, et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res. 2004;64(15):5270–82.PubMedCrossRef
67.
Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol. 2010;28(2):245–55.PubMedCrossRef
68.
Bublik DR, Bursać S, Sheffer M, et al. Regulatory module involving FGF13, miR-504, and p53 regulates ribosomal biogenesis and supports cancer cell survival. Proc Natl Acad Sci USA. 2016;114(4):201614876.
69.
70.
71.
Schuuring E. The involvement of the chromosome 11q13 region in human malignancies: cyclin D1, and EMS1, are two new candidate oncogenes-a review. Gene. 1995;159(1):83–96.PubMedCrossRef
72.
Ormandy CJ, Musgrove EA, Hui R, et al. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat. 2003;78(3):323–35.PubMedCrossRef
73.
Bertoni F, Rinaldi A, Zucca E, et al. Update on the molecular biology of mantle cell lymphoma. Hematol Oncol. 2006;24(1):22–7.PubMedCrossRef
74.
Jin M, Inoue S, Umemura T, et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer. 2001;34(2):207–18.PubMedCrossRef
75.
76.
Musgrove EA. Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Fact. 2006;24(1):13.CrossRef
77.
Shamma A, Doki Y, Shiozaki H, et al. Cyclin D1 overexpression in esophageal dysplasia: a possible biomarker for carcinogenesis of esophageal squamous cell carcinoma. Int J Oncol. 2000;16(2):261.PubMed
78.
Chen James C, Perez-Lorenzo Rolando, Saenger Yvonne M, Drake Charles G, Christiano Angela M. IKZF1 enhances immune infiltrate recruitment in solid tumors and susceptibility to immunotherapy. Cell Systems. 2018;7(1):92–103.PubMedCrossRef
79.
Fan Jie, Yang Michelle X, Ouyang Qi, Deliang Fu, Zude Xu, Liu Xiuping, Mino-Kenudson Mari, Geng Jiang, Tang Feng. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma. Hum Pathol. 2016;55:151–8.PubMedCrossRef
80.
Lin X, Duan X, Liang YY, Su Y, Wrighton KH, Long J, Hu M, Davis CM, Wang J, Brunicardi FC, Shi Y, Chen YG, Meng A, Feng XH. PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling. Cell. 2006;125(5):915–28.PubMedPubMedCentralCrossRef
81.
Cheng A, Kaldis P, Solomon MJ. Dephosphorylation of human cyclin-dependent kinases by protein phosphatase type 2C alpha and beta 2 isoforms. J Biol Chem. 2000;275:34744–9.PubMedCrossRef
82.
Ofek P, Ben-Meir D, Kariv-Inbal Z, et al. Cell cycle regulation and p53 activation by protein phosphatase 2C alpha. J Biol Chem. 2003;278:14299–305.PubMedCrossRef
83.
Shohat M, Ben-Meir D, Lavi S. Protein phosphatase magnesium dependent 1 A (PPM1A) plays a role in the differentiation and survival processes of nerve cells. PLoS ONE. 2012;7:e32438.PubMedPubMedCentralCrossRef
84.
Lu X, An H, Jin R, et al. PPM1A is a RelA phosphatase with tumor suppressor-like activity. Oncogene. 2014;33(22):2918.PubMedCrossRef
85.
Lu X, An H, Jin R, et al. PPM1A is a RelA phosphatase with tumor suppressor-like activity. Oncogene. 2014;33:2918–27.PubMedCrossRef
86.
Dong C, Yuan T, Wu Y, et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer Canc. Cell. 2013;23:316–31.
87.
88.
Lapointe J, Li C, Higgins JP, Van De Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci. 2014;101:811–6.CrossRef
89.
Liu P, Ramachandran S, Seyed MA, Scharer CD, Laycock N, Dalton WB, Williams H, Karanam S, Datta MW, Jaye DL, Moreno CS. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res. 2006;46:4011–9.CrossRef
90.
Jansz Natasha, Chen Kelan, Murphy James M, Blewitt Marnie E. The epigenetic regulator SMCHD1 in development and disease. Trends Genet. 2017;33(4):233–43.PubMedCrossRef
91.
Jin LY, Dong YM, Wu XM, Cao GX, Wang GL. Versatile and amplified biosensing through enzymatic cascade reaction by coupling alkaline phosphatase in situ generation of photoresponsive nanozyme. Anal Chem. 2015;87:10429–36.PubMedCrossRef
92.
Ramaswamy G, Rao VR, Krishnamoorthy L, Ramesh G, Gomathy R, Renukadevi D. Serum levels of bone alkaline phosphatase in breast and prostate cancers with bone metastasis. Indian J Clin Biochem. 2000;15:110.PubMedPubMedCentralCrossRef
93.
Lin XY, Choi MS, Porter AG. Expression analysis of the human caspase-1 subfamily reveals specific regulation of the CASP5 gene by lipopolysaccharide and interferon-gamma. J Biol Chem. 2000;275:39920–6.PubMedCrossRef
94.
Connolly DJ, Bowie AG. The emerging role of human PYHIN proteins in innate immunity: Implications for health and disease. Biochem Pharmacol. 2014;92(3):405–14.PubMedCrossRef
95.
Wang X, Pei L, Yan H, Wang Z, Wei N, Wang S, et al. Intervention of death-associated protein kinase 1-p53 interaction exerts the therapeutic effects against stroke. Stroke. 2014;45(10):3089–91.PubMedCrossRef
96.
Pei L, Shang Y, Jin H, Wang S, Wei N, Yan H, et al. DAPK1-p53 interaction converges necrotic and apoptotic pathways of ischemic neuronal death. J Neurosci. 2014;34(19):6546–56.PubMedCrossRefPubMedCentral
97.
Pei L, Wang S, Jin H, Bi L, Wei N, Yan H, et al. A novel mechanism of spine damages in stroke via DAPK1 and Tau Cereb. Cortex. 2015;25(11):4559–71.CrossRef
98.
Kang BN, Ahmad AS, Saleem S, et al. Death-associated protein kinase-mediated cell death modulated by interaction with DANGER. J Neurosci. 2010;30(1):93–8.PubMedPubMedCentralCrossRef
99.
Keller Nadine, Ozmadenci Duygu, Ichim Gabriel, Stupack Dwayne. Caspase-8 function, and phosphorylation, in cell migration. Semin Cell Dev Biol. 2018;82:105–17.PubMedCrossRef
Metadata
Title
Combined analysis and validation for DNA methylation and gene expression profiles associated with prostate cancer
Authors
Yanqiu Tong
Yang Song
Shixiong Deng
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2019
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-019-0753-x

Other articles of this Issue 1/2019

Cancer Cell International 1/2019 Go to the issue

Primary research

LncRNA TUBA4B functions as a competitive endogenous RNA to inhibit gastric cancer progression by elevating PTEN via sponging miR-214 and miR-216a/b

Primary research

Up-regulated lncRNA XIST contributes to progression of cervical cancer via regulating miR-140-5p and ORC1

Primary research

An improved advanced fragment analysis-based classification and risk stratification of pediatric acute lymphoblastic leukemia

Primary research

MBD1 promotes the malignant behavior of gallbladder cancer cells and induces chemotherapeutic resistance to gemcitabine

Primary research

Expression profile analysis identifies IER3 to predict overall survival and promote lymph node metastasis in tongue cancer

Review

Why are olfactory ensheathing cell tumors so rare?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits